Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | PDE2A | O00408 | 10/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920683 | 0.96 | MAPK1 (0.44) | MAPK1NPC1MAPTRAB9A | |
| SCHEMBL9920823 | 0.90 | MAPK1 (0.42) | MAPK1NPC1MAPTRAB9A | |
| SCHEMBL9920709 | 0.90 | MAPK1 (0.42) | MAPK1NPC1MAPTRAB9A | |
| SCHEMBL9920924 | 0.90 | MAPK1 (0.42) | MAPK1NPC1MAPTRAB9A | |
| SCHEMBL9920651 | 0.88 | MAPK1 (0.44) | MAPK1NPC1MAPTRAB9A | |
| SCHEMBL19041588 | 0.86 | PDE2A (0.38) | MAPK1PDE2ATRPV1 | |
| SCHEMBL9921009 | 0.85 | MAPK3 (0.44) | MAPK1PDE2ANPC1MAPTRAB9A | |
| SCHEMBL9920668 | 0.84 | MAPK1 (0.42) | MAPK1PDE2ANPC1MAPTRAB9A | |
| SCHEMBL19041787 | 0.82 | PDE2A (0.35) | MAPK1PDE2ATRPV1 | |
| SCHEMBL9921110 | 0.81 | PRKAB2 (0.42) | NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648511-B1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9139532-B2 | Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139532-B2 | Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2012078874-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |